Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. filed a Form 8-K dated March 1, 2022 under Item 2.02 to announce financial results for the quarter and year ended December 31, 2021. The filing identifies the company as a Delaware pharmaceutical company headquartered in Florham Park, New Jersey, with common stock traded on Nasdaq under the symbol PHAT.
Financial Metrics
The filing states that a press release announcing the company’s financial results was issued and attached as Exhibit 99.1. The provided filing text does not include the underlying press release or clear values for revenue, net income or loss, cash flow, margins, debt, cash, liquidity, or other financial metrics.
Material Changes Versus the Prior Comparable Period
The filing text does not provide comparative financial results or describe material changes versus the prior quarter or year.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide guidance, outlook commentary, risk updates, contingencies, or unusual items. It only incorporates by reference the March 1, 2022 press release for the announced financial results.
The information in the Form 8-K and Exhibit 99.1 is furnished under Item 2.02 and, pursuant to Form 8-K instructions, is not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings unless specifically referenced.
Investor Verification Items
- Obtain and review Exhibit 99.1, the March 1, 2022 press release, for the actual quarterly and annual financial results.
- Verify cash, cash equivalents, operating cash burn, debt, and expected liquidity runway as of December 31, 2021.
- Review any management guidance, development-program updates, and forward-looking statements contained in the press release.
- Confirm year-over-year and quarter-over-quarter changes in operating expenses, net loss, and research and development spending.